MUMBAI, India, Aug. 8 -- Intellectual Property India has published a patent application (202517042217 A) filed by Tubulis Gmbh, Planegg, Germany, on May 1, for 'novel anti-napi2b antibodies and antibody-drug-conjugates based thereon, therapeutic methods and uses thereof.'
Inventor(s) include Helma-Smets, Jonas; Vogl, Annette; Mai, Isabelle; Herterich, Sarah; Schumacher, Dominik; Kasper, Marc-Andr; Cyprys, Philipp; Gerlach, Marcus; and Schmitt, Saskia.
The application for the patent was published on Aug. 8, under issue no. 32/2025.
According to the abstract released by the Intellectual Property India: "The present invention relates to novel anti-NaPi2b antibodies, antibody-drug-conjugates (ADCs) based thereon as well as to therapeutic methods and uses thereof, particularly in relation to cancer treatment."
The patent application was internationally filed on Oct. 18, 2023, under International application No.PCT/EP2023/079017.
Disclaimer: Curated by HT Syndication.
